Applications of Liquid Biopsies in Non-Small-Cell Lung Cancer
Abstract
:1. Introduction
2. ctDNA—Properties and Analysis
3. Prediction of Response to Targeted Therapy
3.1. EGFR Inhibitors
3.2. ALK/ROS Inhibitors
3.3. RET Inhibitors
3.4. BRAF/MEK Inhibitors
3.5. MET Inhibitors
4. Prediction of Response to Immunotherapy
5. Prediction of Response to Chemotherapy
6. Monitoring of the Disease Course and Effect of the Therapy
6.1. EGFR Inhibitors
6.2. ALK Inhibitors
6.3. Immunotherapy (Anti-PD1/PDL1)
6.4. Chemotherapy
6.5. Radiotherapy
7. Further Use of ctDNA in NSCLC
7.1. NSCLC Diagnosis
7.2. Assessment of Tumor Burden
7.3. Estimation of Prognosis
7.4. Prediction and Detection of Recurrence after Tumor Resection
7.5. ctDNA Detection from Cerebrospinal Fluid
7.6. ctDNA Detection from Urine
8. Conclusions
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Conflicts of Interest
References
- Sung, H.; Ferlay, J.; Siegel, R.L.; Laversanne, M.; Soerjomataram, I.; Jemal, A.; Bray, F. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA. Cancer J. Clin. 2021, 71, 209–249. [Google Scholar] [CrossRef] [PubMed]
- European Lung White Book. Available online: https://www.erswhitebook.org/ (accessed on 24 February 2022).
- Sher, T.; Dy, G.K.; Adjei, A.A. Small Cell Lung Cancer. Mayo Clin. Proc. 2008, 83, 355–367. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Uramoto, H.; Tanaka, F. Recurrence after Surgery in Patients with NSCLC. Transl. Lung Cancer Res. 2014, 3, 242–249. [Google Scholar] [CrossRef] [PubMed]
- Martins, I.; Ribeiro, I.P.; Jorge, J.; Gonçalves, A.C.; Sarmento-Ribeiro, A.B.; Melo, J.B.; Carreira, I.M. Liquid Biopsies: Applications for Cancer Diagnosis and Monitoring. Genes 2021, 12, 349. [Google Scholar] [CrossRef]
- Cristofanilli, M.; Budd, G.T.; Ellis, M.J.; Stopeck, A.; Matera, J.; Miller, M.C.; Reuben, J.M.; Doyle, G.V.; Allard, W.J.; Terstappen, L.W.M.M.; et al. Circulating Tumor Cells, Disease Progression, and Survival in Metastatic Breast Cancer. N. Engl. J. Med. 2004, 351, 781–791. [Google Scholar] [CrossRef] [Green Version]
- Schwarzenbach, H.; Hoon, D.S.B.; Pantel, K. Cell-Free Nucleic Acids as Biomarkers in Cancer Patients. Nat. Rev. Cancer 2011, 11, 426–437. [Google Scholar] [CrossRef]
- Anfossi, S.; Babayan, A.; Pantel, K.; Calin, G.A. Clinical Utility of Circulating Non-Coding RNAs—An Update. Nat. Rev. Clin. Oncol. 2018, 15, 541–563. [Google Scholar] [CrossRef]
- Fleischhacker, M.; Beinert, T.; Ermitsch, M.; Seferi, D.; Possinger, K.; Engelmann, C.; Jandrig, B. Detection of Amplifiable Messenger RNA in the Serum of Patients with Lung Cancer. Ann. N. Y. Acad. Sci. 2001, 945, 179–188. [Google Scholar] [CrossRef]
- Wang, N.; Song, X.; Liu, L.; Niu, L.; Wang, X.; Song, X.; ** and Monitoring of Anaplastic Lymphoma Kinase (ALK) Rearranged Non-Small Cell Lung Cancer by Capture-Based next-Generation Sequencing. Oncotarget 2016, 7, 65208–65217. [Google Scholar] [CrossRef] [Green Version]
- Bordi, P.; Tiseo, M.; Rofi, E.; Petrini, I.; Restante, G.; Danesi, R.; Del Re, M. Detection of ALK and KRAS Mutations in Circulating Tumor DNA of Patients with Advanced ALK-Positive NSCLC with Disease Progression During Crizotinib Treatment. Clin. Lung Cancer 2017, 18, 692–697. [Google Scholar] [CrossRef]
- Dagogo-Jack, I.; Rooney, M.; Nagy, R.J.; Lin, J.J.; Chin, E.; Ferris, L.A.; Ackil, J.; Lennerz, J.K.; Lanman, R.B.; Gainor, J.F.; et al. Molecular Analysis of Plasma from Patients with ROS1-Positive NSCLC. J. Thorac. Oncol. 2019, 14, 816–824. [Google Scholar] [CrossRef]
- Mezquita, L.; Swalduz, A.; Jovelet, C.; Ortiz-Cuaran, S.; Howarth, K.; Planchard, D.; Avrillon, V.; Recondo, G.; Marteau, S.; Benitez, J.C.; et al. Clinical Relevance of an Amplicon-Based Liquid Biopsy for Detecting ALK and ROS1 Fusion and Resistance Mutations in Patients with Non–Small-Cell Lung Cancer. JCO Precis. Oncol. 2020, 4, 272–282. [Google Scholar] [CrossRef]
- Horn, L.; Whisenant, J.G.; Wakelee, H.; Reckamp, K.L.; Qiao, H.; Leal, T.A.; Du, L.; Hernandez, J.; Huang, V.; Blumenschein, G.R.; et al. Monitoring Therapeutic Response and Resistance: Analysis of Circulating Tumor DNA in Patients with ALK+ Lung Cancer. J. Thorac. Oncol. 2019, 14, 1901–1911. [Google Scholar] [CrossRef]
- Wang, R.; Hu, H.; Pan, Y.; Li, Y.; Ye, T.; Li, C.; Luo, X.; Wang, L.; Li, H.; Zhang, Y.; et al. RET Fusions Define a Unique Molecular and Clinicopathologic Subtype of Non–Small-Cell Lung Cancer. J. Clin. Oncol. 2012, 30, 4352–4359. [Google Scholar] [CrossRef]
- Drilon, A.; Wang, L.; Arcila, M.E.; Balasubramanian, S.; Greenbowe, J.R.; Ross, J.S.; Stephens, P.; Lipson, D.; Miller, V.A.; Kris, M.G.; et al. Broad, Hybrid Capture–Based Next-Generation Sequencing Identifies Actionable Genomic Alterations in Lung Adenocarcinomas Otherwise Negative for Such Alterations by Other Genomic Testing Approaches. Clin. Cancer Res. 2015, 21, 3631–3639. [Google Scholar] [CrossRef] [Green Version]
- Piotrowska, Z.; Isozaki, H.; Lennerz, J.K.; Gainor, J.F.; Lennes, I.T.; Zhu, V.W.; Marcoux, N.; Banwait, M.K.; Digumarthy, S.R.; Su, W.; et al. Landscape of Acquired Resistance to Osimertinib in EGFR-Mutant NSCLC and Clinical Validation of Combined EGFR and RET Inhibition with Osimertinib and BLU-667 for Acquired RET Fusion. Cancer Discov. 2018, 8, 1529–1539. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Rich, T.A.; Reckamp, K.L.; Chae, Y.K.; Doebele, R.C.; Iams, W.T.; Oh, M.; Raymond, V.M.; Lanman, R.B.; Riess, J.W.; Stinchcombe, T.E.; et al. Analysis of Cell-Free DNA from 32,989 Advanced Cancers Reveals Novel Co-Occurring Activating RET Alterations and Oncogenic Signaling Pathway Aberrations. Clin. Cancer Res. 2019, 25, 5832–5842. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Subbiah, V.; Yang, D.; Velcheti, V.; Drilon, A.; Meric-Bernstam, F. State-of-the-Art Strategies for Targeting RET-Dependent Cancers. J. Clin. Oncol. 2020, 38, 1209–1221. [Google Scholar] [CrossRef] [PubMed]
- Gautschi, O.; Milia, J.; Filleron, T.; Wolf, J.; Carbone, D.P.; Owen, D.; Camidge, R.; Narayanan, V.; Doebele, R.C.; Besse, B.; et al. Targeting RET in Patients with RET-Rearranged Lung Cancers: Results from the Global, Multicenter RET Registry. J. Clin. Oncol. 2017, 35, 1403–1410. [Google Scholar] [CrossRef] [Green Version]
- Sarfaty, M.; Moore, A.; Neiman, V.; Dudnik, E.; Ilouze, M.; Gottfried, M.; Katznelson, R.; Nechushtan, H.; Sorotsky, H.G.; Paz, K.; et al. RET Fusion Lung Carcinoma: Response to Therapy and Clinical Features in a Case Series of 14 Patients. Clin. Lung Cancer 2017, 18, e223–e232. [Google Scholar] [CrossRef]
- Solomon, B.J.; Tan, L.; Lin, J.J.; Wong, S.Q.; Hollizeck, S.; Ebata, K.; Tuch, B.B.; Yoda, S.; Gainor, J.F.; Sequist, L.V.; et al. RET Solvent Front Mutations Mediate Acquired Resistance to Selective RET Inhibition in RET-Driven Malignancies. J. Thorac. Oncol. 2020, 15, 541–549. [Google Scholar] [CrossRef] [Green Version]
- Barlesi, F.; Mazieres, J.; Merlio, J.-P.; Debieuvre, D.; Mosser, J.; Lena, H.; Ouafik, L.; Besse, B.; Rouquette, I.; Westeel, V.; et al. Routine Molecular Profiling of Patients with Advanced Non-Small-Cell Lung Cancer: Results of a 1-Year Nationwide Programme of the French Cooperative Thoracic Intergroup (IFCT). Lancet 2016, 387, 1415–1426. [Google Scholar] [CrossRef]
- Paik, P.K.; Arcila, M.E.; Fara, M.; Sima, C.S.; Miller, V.A.; Kris, M.G.; Ladanyi, M.; Riely, G.J. Clinical Characteristics of Patients with Lung Adenocarcinomas Harboring BRAF Mutations. J. Clin. Oncol. 2011, 29, 2046–2051. [Google Scholar] [CrossRef] [Green Version]
- Alvarez, J.G.B.; Otterson, G.A. Agents to Treat BRAF-Mutant Lung Cancer. Drugs Context 2019, 8, 212566. [Google Scholar] [CrossRef]
- Maemondo, M.; Inoue, A.; Kobayashi, K.; Sugawara, S.; Oizumi, S.; Isobe, H.; Gemma, A.; Harada, M.; Yoshizawa, H.; Kinoshita, I.; et al. Gefitinib or Chemotherapy for Non–Small-Cell Lung Cancer with Mutated EGFR. N. Engl. J. Med. 2010, 362, 2380–2388. [Google Scholar] [CrossRef] [Green Version]
- Rosell, R.; Carcereny, E.; Gervais, R.; Vergnenegre, A.; Massuti, B.; Felip, E.; Palmero, R.; Garcia-Gomez, R.; Pallares, C.; Sanchez, J.M.; et al. Erlotinib versus Standard Chemotherapy as First-Line Treatment for European Patients with Advanced EGFR Mutation-Positive Non-Small-Cell Lung Cancer (EURTAC): A Multicentre, Open-Label, Randomised Phase 3 Trial. Lancet Oncol. 2012, 13, 239–246. [Google Scholar] [CrossRef]
- Chung, C. Tyrosine Kinase Inhibitors for Epidermal Growth Factor Receptor Gene Mutation–positive Non-Small Cell Lung Cancers: An Update for Recent Advances in Therapeutics. J. Oncol. Pharm. Pract. 2016, 22, 461–476. [Google Scholar] [CrossRef]
- Yang, Y.; Shen, X.; Li, R.; Shen, J.; Zhang, H.; Yu, L.; Liu, B.; Wang, L. The Detection and Significance of EGFR and BRAF in Cell-Free DNA of Peripheral Blood in NSCLC. Oncotarget 2017, 8, 49773–49782. [Google Scholar] [CrossRef] [Green Version]
- Ortiz-Cuaran, S.; Mezquita, L.; Swalduz, A.; Aldea, M.; Mazieres, J.; Leonce, C.; Jovelet, C.; Pradines, A.; Avrillon, V.; Chumbi Flores, W.R.; et al. Circulating Tumor DNA Genomics Reveal Potential Mechanisms of Resistance to BRAF-Targeted Therapies in Patients with BRAF-Mutant Metastatic Non–Small Cell Lung Cancer. Clin. Cancer Res. 2020, 26, 6242–6253. [Google Scholar] [CrossRef]
- Blumenschein, G.R.; Mills, G.B.; Gonzalez-Angulo, A.M. Targeting the Hepatocyte Growth Factor-cMET Axis in Cancer Therapy. J. Clin. Oncol. 2012, 30, 3287–3296. [Google Scholar] [CrossRef] [Green Version]
- Sadiq, A.A.; Salgia, R. MET as a Possible Target for Non-Small-Cell Lung Cancer. J. Clin. Oncol. 2013, 31, 1089–1096. [Google Scholar] [CrossRef] [Green Version]
- Engelman, J.A.; Zejnullahu, K.; Mitsudomi, T.; Song, Y.; Hyland, C.; Park, J.O.; Lindeman, N.; Gale, C.-M.; Zhao, X.; Christensen, J.; et al. MET Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling. Science 2007, 316, 1039–1043. [Google Scholar] [CrossRef]
- Frampton, G.M.; Ali, S.M.; Rosenzweig, M.; Chmielecki, J.; Lu, X.; Bauer, T.M.; Akimov, M.; Bufill, J.A.; Lee, C.; Jentz, D.; et al. Activation of MET via Diverse Exon 14 Splicing Alterations Occurs in Multiple Tumor Types and Confers Clinical Sensitivity to MET Inhibitors. Cancer Discov. 2015, 5, 850–859. [Google Scholar] [CrossRef] [Green Version]
- Paik, P.K.; Drilon, A.; Fan, P.-D.; Yu, H.; Rekhtman, N.; Ginsberg, M.S.; Borsu, L.; Schultz, N.; Berger, M.F.; Rudin, C.M.; et al. Response to MET Inhibitors in Patients with Stage IV Lung Adenocarcinomas Harboring MET Mutations Causing Exon 14 Skip**. Cancer Discov. 2015, 5, 842–849. [Google Scholar] [CrossRef] [Green Version]
- Li, A.; Yang, J.-J.; Zhang, X.-C.; Zhang, Z.; Su, J.; Gou, L.-Y.; Bai, Y.; Zhou, Q.; Yang, Z.; Han-Zhang, H.; et al. Acquired MET Y1248H and D1246N Mutations Mediate Resistance to MET Inhibitors in Non-Small Cell Lung Cancer. Clin. Cancer Res. 2017, 23, 4929–4937. [Google Scholar] [CrossRef] [Green Version]
- Brahmer, J.; Reckamp, K.L.; Baas, P.; Crinò, L.; Eberhardt, W.E.E.; Poddubskaya, E.; Antonia, S.; Pluzanski, A.; Vokes, E.E.; Holgado, E.; et al. Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer. N. Engl. J. Med. 2015, 373, 123–135. [Google Scholar] [CrossRef] [Green Version]
- Gandhi, L.; Rodríguez-Abreu, D.; Gadgeel, S.; Esteban, E.; Felip, E.; De Angelis, F.; Domine, M.; Clingan, P.; Hochmair, M.J.; Powell, S.F.; et al. Pembrolizumab plus Chemotherapy in Metastatic Non–Small-Cell Lung Cancer. N. Engl. J. Med. 2018, 378, 2078–2092. [Google Scholar] [CrossRef]
- Borghaei, H.; Paz-Ares, L.; Horn, L.; Spigel, D.R.; Steins, M.; Ready, N.E.; Chow, L.Q.; Vokes, E.E.; Felip, E.; Holgado, E.; et al. Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer. N. Engl. J. Med. 2015, 373, 1627–1639. [Google Scholar] [CrossRef]
- Paz-Ares, L.; Luft, A.; Vicente, D.; Tafreshi, A.; Gümüş, M.; Mazières, J.; Hermes, B.; Çay Şenler, F.; Csőszi, T.; Fülöp, A.; et al. Pembrolizumab plus Chemotherapy for Squamous Non–Small-Cell Lung Cancer. N. Engl. J. Med. 2018, 379, 2040–2051. [Google Scholar] [CrossRef]
- Savill, K.M.Z.; Zettler, M.E.; Feinberg, B.A.; Jeune-Smith, Y.; Gajra, A. Awareness and Utilization of Tumor Mutation Burden (TMB) as a Biomarker for Administration of Immuno-Oncology (I-O) Therapeutics by Practicing Community Oncologists in the United States (U.S.). J. Clin. Oncol. 2021, 39, 2608. [Google Scholar] [CrossRef]
- Büttner, R.; Longshore, J.W.; López-Ríos, F.; Merkelbach-Bruse, S.; Normanno, N.; Rouleau, E.; Penault-Llorca, F. Implementing TMB Measurement in Clinical Practice: Considerations on Assay Requirements. ESMO Open 2019, 4, e000442. [Google Scholar] [CrossRef] [Green Version]
- Vilimas, T. Measuring Tumor Mutational Burden Using Whole-Exome Sequencing. Methods Mol. Biol. Clifton N. J. 2020, 2055, 63–91. [Google Scholar] [CrossRef]
- Fancello, L.; Gandini, S.; Pelicci, P.G.; Mazzarella, L. Tumor Mutational Burden Quantification from Targeted Gene Panels: Major Advancements and Challenges. J. Immunother. Cancer 2019, 7, 183. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Friedlaender, A.; Nouspikel, T.; Christinat, Y.; Ho, L.; McKee, T.; Addeo, A. Tissue-Plasma TMB Comparison and Plasma TMB Monitoring in Patients with Metastatic Non-Small Cell Lung Cancer Receiving Immune Checkpoint Inhibitors. Front. Oncol. 2020, 10, 142. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Gandara, D.R.; Paul, S.M.; Kowanetz, M.; Schleifman, E.; Zou, W.; Li, Y.; Rittmeyer, A.; Fehrenbacher, L.; Otto, G.; Malboeuf, C.; et al. Blood-Based Tumor Mutational Burden as a Predictor of Clinical Benefit in Non-Small-Cell Lung Cancer Patients Treated with Atezolizumab. Nat. Med. 2018, 24, 1441–1448. [Google Scholar] [CrossRef]
- Chae, Y.K.; Davis, A.A.; Agte, S.; Pan, A.; Simon, N.I.; Iams, W.T.; Cruz, M.R.; Tamragouri, K.; Rhee, K.; Mohindra, N.; et al. Clinical Implications of Circulating Tumor DNA Tumor Mutational Burden (ctDNA TMB) in Non-Small Cell Lung Cancer. Oncologist 2019, 24, 820–828. [Google Scholar] [CrossRef] [Green Version]
- Wang, Z.; Duan, J.; Wang, G.; Zhao, J.; Xu, J.; Han, J.; Zhao, Z.; Zhao, J.; Zhu, B.; Zhuo, M.; et al. Allele Frequency-Adjusted Blood-Based Tumor Mutational Burden as a Predictor of Overall Survival for Patients with NSCLC Treated with PD-(L)1 Inhibitors. J. Thorac. Oncol. 2020, 15, 556–567. [Google Scholar] [CrossRef]
- Rosell, R.; Gomez-Codina, J.; Camps, C.; Maestre, J.; Padille, J.; Canto, A.; Mate, J.L.; Li, S.; Roig, J.; Olazabal, A.; et al. A Randomized Trial Comparing Preoperative Chemotherapy Plus Surgery with Surgery Alone in Patients with Non-Small-Cell Lung Cancer. N. Engl. J. Med. 1994, 330, 153–158. [Google Scholar] [CrossRef] [Green Version]
- Roth, J.A.; Fossella, F.; Komaki, R.; Ryan, M.B.; Putnam, J.B.; Lee, J.S.; Dhingra, H.; De Caro, L.; Chasen, M.; McGavran, M.; et al. A Randomized Trial Comparing Perioperative Chemotherapy and Surgery with Surgery Alone in Resectable Stage IIIA Non-Small-Cell Lung Cancer. JNCI J. Natl. Cancer Inst. 1994, 86, 673–680. [Google Scholar] [CrossRef]
- Coco, S.; Alama, A.; Vanni, I.; Fontana, V.; Genova, C.; Dal Bello, M.G.; Truini, A.; Rijavec, E.; Biello, F.; Sini, C.; et al. Circulating Cell-Free DNA and Circulating Tumor Cells as Prognostic and Predictive Biomarkers in Advanced Non-Small Cell Lung Cancer Patients Treated with First-Line Chemotherapy. Int. J. Mol. Sci. 2017, 18, 1035. [Google Scholar] [CrossRef] [Green Version]
- Han, X.; Han, Y.; Tan, Q.; Huang, Y.; Yang, J.; Yang, S.; He, X.; Zhou, S.; Song, Y.; Pi, J.; et al. Tracking Longitudinal Genetic Changes of Circulating Tumor DNA (ctDNA) in Advanced Lung Adenocarcinoma Treated with Chemotherapy. J. Transl. Med. 2019, 17, 339. [Google Scholar] [CrossRef]
- Xu, R.; Zhong, G.; Huang, T.; He, W.; Kong, C.; Zhang, X.; Wang, Y.; Liu, M.; Xu, M.; Chen, S. Sequencing of Circulating Tumor DNA for Dynamic Monitoring of Gene Mutations in Advanced Non-Small Cell Lung Cancer. Oncol. Lett. 2018, 15, 3726–3734. [Google Scholar] [CrossRef] [Green Version]
- Chiou, C.-C.; Wang, C.-L.; Luo, J.-D.; Liu, C.-Y.; Ko, H.-W.; Yang, C.-T. Targeted Sequencing of Circulating Cell Free DNA Can Be Used to Monitor Therapeutic Efficacy of Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancer Patients. Cancer Genom.-Proteom. 2020, 17, 417–423. [Google Scholar] [CrossRef]
- Sakai, K.; Takahama, T.; Shimokawa, M.; Azuma, K.; Takeda, M.; Kato, T.; Daga, H.; Okamoto, I.; Akamatsu, H.; Teraoka, S.; et al. Predicting Osimertinib-treatment Outcomes through EGFR Mutant-fraction Monitoring in the Circulating Tumor DNA of EGFR T790M-positive Patients with Non-small Cell Lung Cancer (WJOG8815L). Mol. Oncol. 2021, 15, 126–137. [Google Scholar] [CrossRef]
- Iwama, E.; Sakai, K.; Azuma, K.; Harada, T.; Harada, D.; Nosaki, K.; Hotta, K.; Ohyanagi, F.; Kurata, T.; Fukuhara, T.; et al. Monitoring of Somatic Mutations in Circulating Cell-Free DNA by Digital PCR and next-Generation Sequencing during Afatinib Treatment in Patients with Lung Adenocarcinoma Positive for EGFR Activating Mutations. Ann. Oncol. 2017, 28, 136–141. [Google Scholar] [CrossRef]
- Dietz, S.; Christopoulos, P.; Yuan, Z.; Angeles, A.K.; Gu, L.; Volckmar, A.-L.; Ogrodnik, S.J.; Janke, F.; Fratte, C.D.; Zemojtel, T.; et al. Longitudinal Therapy Monitoring of ALK-Positive Lung Cancer by Combined Copy Number and Targeted Mutation Profiling of Cell-Free DNA. EBioMedicine 2020, 62, 103103. [Google Scholar] [CrossRef] [PubMed]
- Hodi, F.S.; Sznol, M.; Kluger, H.M.; McDermott, D.F.; Carvajal, R.D.; Lawrence, D.P.; Topalian, S.L.; Atkins, M.B.; Powderly, J.D.; Sharfman, W.H.; et al. Long-Term Survival of Ipilimumab-Naive Patients (pts) with Advanced Melanoma (MEL) Treated with Nivolumab (anti-PD-1, BMS-936558, ONO-4538) in a Phase I Trial. J. Clin. Oncol. 2014, 32, 9002. [Google Scholar] [CrossRef]
- Guibert, N.; Mazières, J. Nivolumab for Treating Non-Small Cell Lung Cancer. Expert Opin. Biol. Ther. 2015, 15, 1789–1797. [Google Scholar] [CrossRef] [PubMed]
- Goldberg, S.B.; Narayan, A.; Kole, A.J.; Decker, R.H.; Teysir, J.; Carriero, N.J.; Lee, A.; Nemati, R.; Nath, S.K.; Mane, S.M.; et al. Early Assessment of Lung Cancer Immunotherapy Response via Circulating Tumor DNA. Clin. Cancer Res. 2018, 24, 1872–1880. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Guibert, N.; Mazieres, J.; Delaunay, M.; Casanova, A.; Farella, M.; Keller, L.; Favre, G.; Pradines, A. Monitoring of KRAS-Mutated ctDNA to Discriminate Pseudo-Progression from True Progression during Anti-PD-1 Treatment of Lung Adenocarcinoma. Oncotarget 2017, 8, 38056–38060. [Google Scholar] [CrossRef] [Green Version]
- Anagnostou, V.; Forde, P.M.; White, J.R.; Niknafs, N.; Hruban, C.; Naidoo, J.; Marrone, K.; Sivakumar, I.K.A.; Bruhm, D.C.; Rosner, S.; et al. Dynamics of Tumor and Immune Responses during Immune Checkpoint Blockade in Non-Small Cell Lung Cancer. Cancer Res. 2019, 79, 1214–1225. [Google Scholar] [CrossRef] [Green Version]
- Jiang, T.; Li, X.; Wang, J.; Su, C.; Han, W.; Zhao, C.; Wu, F.; Gao, G.; Li, W.; Chen, X.; et al. Mutational Landscape of cfDNA Identifies Distinct Molecular Features Associated with Therapeutic Response to First-Line Platinum-Based Doublet Chemotherapy in Patients with Advanced NSCLC. Theranostics 2017, 7, 4753–4762. [Google Scholar] [CrossRef]
- Guibert, N.; Pradines, A.; Farella, M.; Casanova, A.; Gouin, S.; Keller, L.; Favre, G.; Mazieres, J. Monitoring KRAS Mutations in Circulating DNA and Tumor Cells Using Digital Droplet PCR during Treatment of KRAS-Mutated Lung Adenocarcinoma. Lung Cancer 2016, 100, 1–4. [Google Scholar] [CrossRef]
- Kageyama, S.-I.; Nihei, K.; Karasawa, K.; Sawada, T.; Koizumi, F.; Yamaguchi, S.; Kato, S.; Hojo, H.; Motegi, A.; Tsuchihara, K.; et al. Radiotherapy Increases Plasma Levels of Tumoral Cell-Free DNA in Non-Small Cell Lung Cancer Patients. Oncotarget 2018, 9, 19368–19378. [Google Scholar] [CrossRef] [Green Version]
- Walls, G.M.; McConnell, L.; McAleese, J.; Murray, P.; Lynch, T.B.; Savage, K.; Hanna, G.G.; de Castro, D.G. Early Circulating Tumour DNA Kinetics Measured by Ultra-Deep next-Generation Sequencing during Radical Radiotherapy for Non-Small Cell Lung Cancer: A Feasibility Study. Radiat. Oncol. 2020, 15, 132. [Google Scholar] [CrossRef]
- Cohen, J.D.; Li, L.; Wang, Y.; Thoburn, C.; Afsari, B.; Danilova, L.; Douville, C.; Javed, A.A.; Wong, F.; Mattox, A.; et al. Detection and Localization of Surgically Resectable Cancers with a Multi-Analyte Blood Test. Science 2018, 359, 926–930. [Google Scholar] [CrossRef] [Green Version]
- Locke, W.J.; Guanzon, D.; Ma, C.; Liew, Y.J.; Duesing, K.R.; Fung, K.Y.C.; Ross, J.P. DNA Methylation Cancer Biomarkers: Translation to the Clinic. Front. Genet. 2019, 10, 1150. [Google Scholar] [CrossRef]
- Yang, Z.; Qi, W.; Sun, L.; Zhou, H.; Zhou, B.; Hu, Y. DNA Methylation Analysis of Selected Genes for the Detection of Early-Stage Lung Cancer Using Circulating Cell-Free DNA. Adv. Clin. Exp. Med. 2019, 28, 355–360. [Google Scholar] [CrossRef] [Green Version]
- Ooki, A.; Maleki, Z.; Tsay, J.-C.J.; Goparaju, C.; Brait, M.; Turaga, N.; Nam, H.-S.; Rom, W.N.; Pass, H.I.; Sidransky, D.; et al. A Panel of Novel Detection and Prognostic Methylated DNA Markers in Primary Non–Small Cell Lung Cancer and Serum DNA. Clin. Cancer Res. 2017, 23, 7141–7152. [Google Scholar] [CrossRef] [Green Version]
- Passiglia, F.; Rizzo, S.; Di Maio, M.; Galvano, A.; Badalamenti, G.; Listì, A.; Gulotta, L.; Castiglia, M.; Fulfaro, F.; Bazan, V.; et al. The Diagnostic Accuracy of Circulating Tumor DNA for the Detection of EGFR-T790M Mutation in NSCLC: A Systematic Review and Meta-Analysis. Sci. Rep. 2018, 8, 13379. [Google Scholar] [CrossRef] [Green Version]
- Czarnecka, A.M.; Brodziak, A.; Sobczuk, P.; Dendek, C.; Labochka, D.; Korniluk, J.; Bartnik, E.; Szczylik, C. Metastatic Tumor Burden and Loci as Predictors of First Line Sunitinib Treatment Efficacy in Patients with Renal Cell Carcinoma. Sci. Rep. 2019, 9, 7754. [Google Scholar] [CrossRef]
- Tateishi, U.; Tatsumi, M.; Terauchi, T.; Ando, K.; Niitsu, N.; Kim, W.S.; Suh, C.; Ogura, M.; Tobinai, K. Prognostic Significance of Metabolic Tumor Burden by Positron Emission Tomography/computed Tomography in Patients with Relapsed/refractory Diffuse Large B-cell Lymphoma. Cancer Sci. 2015, 106, 186–193. [Google Scholar] [CrossRef]
- Gobbi, P.G.; Broglia, C.; Di Giulio, G.; Mantelli, M.; Anselmo, P.; Merli, F.; Zinzani, P.L.; Rossi, G.; Callea, V.; Iannitto, E.; et al. The Clinical Value of Tumor Burden at Diagnosis in Hodgkin Lymphoma. Cancer 2004, 101, 1824–1834. [Google Scholar] [CrossRef]
- Leek, R.D.; Landers, R.J.; Harris, A.L.; Lewis, C.E. Necrosis Correlates with High Vascular Density and Focal Macrophage Infiltration in Invasive Carcinoma of the Breast. Br. J. Cancer 1999, 79, 991–995. [Google Scholar] [CrossRef] [Green Version]
- Diehl, F.; Li, M.; Dressman, D.; He, Y.; Shen, D.; Szabo, S.; Diaz, L.A.; Goodman, S.N.; David, K.A.; Juhl, H.; et al. Detection and Quantification of Mutations in the Plasma of Patients with Colorectal Tumors. Proc. Natl. Acad. Sci. USA 2005, 102, 16368–16373. [Google Scholar] [CrossRef] [Green Version]
- Cho, M.-S.; Park, C.H.; Lee, S.; Park, H.S. Clinicopathological Parameters for Circulating Tumor DNA Shedding in Surgically Resected Non-Small Cell Lung Cancer with EGFR or KRAS Mutation. PLoS ONE 2020, 15, e0230622. [Google Scholar] [CrossRef] [Green Version]
- Zhu, Y.-J.; Zhang, H.-B.; Liu, Y.-H.; Zhang, F.-L.; Zhu, Y.-Z.; Li, Y.; Bai, J.-P.; Liu, L.-R.; Qu, Y.-C.; Qu, X.; et al. Quantitative Cell-Free Circulating EGFR Mutation Concentration Is Correlated with Tumor Burden in Advanced NSCLC Patients. Lung Cancer 2017, 109, 124–127. [Google Scholar] [CrossRef]
- Yanagita, M.; Redig, A.J.; Paweletz, C.P.; Dahlberg, S.E.; O’Connell, A.; Feeney, N.; Taibi, M.; Boucher, D.; Oxnard, G.R.; Johnson, B.E.; et al. A Prospective Evaluation of Circulating Tumor Cells and Cell-Free DNA in EGFR-Mutant Non–Small Cell Lung Cancer Patients Treated with Erlotinib on a Phase II Trial. Clin. Cancer Res. 2016, 22, 6010–6020. [Google Scholar] [CrossRef] [Green Version]
- Chalmers, Z.R.; Connelly, C.F.; Fabrizio, D.; Gay, L.; Ali, S.M.; Ennis, R.; Schrock, A.; Campbell, B.; Shlien, A.; Chmielecki, J.; et al. Analysis of 100,000 Human Cancer Genomes Reveals the Landscape of Tumor Mutational Burden. Genome Med. 2017, 9, 34. [Google Scholar] [CrossRef] [Green Version]
- Heitzer, E.; Ulz, P.; Geigl, J.B. Circulating Tumor DNA as a Liquid Biopsy for Cancer. Clin. Chem. 2015, 61, 112–123. [Google Scholar] [CrossRef]
- Fan, G.; Zhang, K.; Yang, X.; Ding, J.; Wang, Z.; Li, J. Prognostic Value of Circulating Tumor DNA in Patients with Colon Cancer: Systematic Review. PLoS ONE 2017, 12, e0171991. [Google Scholar] [CrossRef] [Green Version]
- Jia, J.; Huang, B.; Zhuang, Z.; Chen, S. Circulating Tumor DNA as Prognostic Markers for Late Stage NSCLC with Bone Metastasis. Int. J. Biol. Markers 2018, 33, 222–230. [Google Scholar] [CrossRef]
- Michaelidou, K.; Koutoulaki, C.; Mavridis, K.; Vorrias, E.; Papadaki, M.A.; Koutsopoulos, A.V.; Mavroudis, D.; Agelaki, S. Detection of KRAS G12/G13 Mutations in Cell Free-DNA by Droplet Digital PCR, Offers Prognostic Information for Patients with Advanced Non-Small Cell Lung Cancer. Cells 2020, 9, 2514. [Google Scholar] [CrossRef]
- Liu, Z.; ** of Cerebrospinal Fluid Associated with Osimertinib Response and Resistance for Leptomeningeal Metastases in EGFR-Mutated NSCLC. J. Thorac. Oncol. 2021, 16, 250–258. [Google Scholar] [CrossRef]
- Botezatu, I.; Serdyuk, O.; Potapova, G.; Shelepov, V.; Alechina, R.; Molyaka, Y.; Ananév, V.; Bazin, I.; Garin, A.; Narimanov, M.; et al. Genetic Analysis of DNA Excreted in Urine: A New Approach for Detecting Specific Genomic DNA Sequences from Cells Dying in an Organism. Clin. Chem. 2000, 46, 1078–1084. [Google Scholar] [CrossRef] [Green Version]
- Reckamp, K.L.; Melnikova, V.O.; Karlovich, C.; Sequist, L.V.; Camidge, D.R.; Wakelee, H.; Perol, M.; Oxnard, G.R.; Kosco, K.; Croucher, P.; et al. A Highly Sensitive and Quantitative Test Platform for Detection of NSCLC EGFR Mutations in Urine and Plasma. J. Thorac. Oncol. Off. Publ. Int. Assoc. Study Lung Cancer 2016, 11, 1690–1700. [Google Scholar] [CrossRef] [Green Version]
- Zhang, H.; He, B.; Cui, J.; Zhao, M.; Zhang, Z. Comparison of Circulating DNA from Plasma and Urine for EGFR Mutations in NSCLC Patients. Cancer Biomark. Sect. Dis. Markers 2018, 23, 427–436. [Google Scholar] [CrossRef]
- Hu, T.; Shen, H.; Huang, H.; Song, M.; Yang, Z.; Zhou, Y.; Zhao, G. Urinary Circulating DNA Profiling in Non-Small Cell Lung Cancer Patients Following Treatment Shows Prognostic Potential. J. Thorac. Dis. 2018, 10, 4137–4146. [Google Scholar] [CrossRef]
- Husain, H.; Melnikova, V.O.; Kosco, K.; Woodward, B.; More, S.; **le, S.C.; Weihe, E.; Park, B.H.; Tewari, M.; Erlander, M.G.; et al. Monitoring Daily Dynamics of Early Tumor Response to Targeted Therapy by Detecting Circulating Tumor DNA in Urine. Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res. 2017, 23, 4716–4723. [Google Scholar] [CrossRef] [Green Version]
- Tchekmedyian, N.; Mudad, R.; Blanco, F.F.; Raymond, V.M.; Garst, J.; Erlander, M.G.; Haura, E.; Berz, D. Longitudinal Monitoring of ctDNA EGFR Mutation Burden from Urine Correlates with Patient Response to EGFR TKIs: A Case Series. Lung Cancer 2017, 108, 22–28. [Google Scholar] [CrossRef]
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations. |
© 2022 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Pesta, M.; Shetti, D.; Kulda, V.; Knizkova, T.; Houfkova, K.; Sharif Bagheri, M.; Svaton, M.; Polivka, J. Applications of Liquid Biopsies in Non-Small-Cell Lung Cancer. Diagnostics 2022, 12, 1799. https://doi.org/10.3390/diagnostics12081799
Pesta M, Shetti D, Kulda V, Knizkova T, Houfkova K, Sharif Bagheri M, Svaton M, Polivka J. Applications of Liquid Biopsies in Non-Small-Cell Lung Cancer. Diagnostics. 2022; 12(8):1799. https://doi.org/10.3390/diagnostics12081799
Chicago/Turabian StylePesta, Martin, Dattatrya Shetti, Vlastimil Kulda, Tereza Knizkova, Katerina Houfkova, Mahyar Sharif Bagheri, Martin Svaton, and Jiri Polivka. 2022. "Applications of Liquid Biopsies in Non-Small-Cell Lung Cancer" Diagnostics 12, no. 8: 1799. https://doi.org/10.3390/diagnostics12081799